Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
Bioanalysis
|
February 17, 2023
A systematic and sensitive method for critical reagent antibody evaluation with PCA technology
Jian Gong, Xing Wang, John Hackmann
BMC Cancer
|
August 27, 2018
RESPONDER - diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial
Joerg Heil, Peter Sinn, Hannah Richter, et al.
Cancer
|
June 26, 2015
A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52)
Gunter von Minckwitz, Bettina Conrad, Toralf Reimer, et al.
Breast Cancer Research : BCR
|
September 2, 2022
Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial
Cornelia Kolberg-Liedtke, Friedrich Feuerhake, Madlen Garke, et al.
International Journal of Cancer
|
June 5, 2019
Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial
Oleg Gluz, Cornelia Kolberg-Liedtke, Aleix Prat, et al.
Breast Cancer Research and Treatment
|
March 19, 2017
Efficacy and safety of nab-paclitaxel 125 mg/m<sup>2</sup> and nab-paclitaxel 150 mg/m<sup>2</sup> compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69)
Jenny Furlanetto, Christian Jackisch, Michael Untch, et al.
Journal for Immunotherapy of Cancer
|
May 8, 2021
Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial
Monika Graeser, Friedrich Feuerhake, Oleg Gluz, et al.
Molecular Cancer
|
March 27, 2025
Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trial
Darren Korbie, Clare Stirzaker, Oleg Gluz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 15, 2019
NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto
Michael Untch, Christian Jackisch, Andreas Schneeweiss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 7, 2022
De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial
Oleg Gluz, Ulrike Nitz, Cornelia Kolberg-Liedtke, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
Bioanalysis
|
February 17, 2023
A systematic and sensitive method for critical reagent antibody evaluation with PCA technology
Jian Gong, Xing Wang, John Hackmann
BMC Cancer
|
August 27, 2018
RESPONDER - diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial
Joerg Heil, Peter Sinn, Hannah Richter, et al.
Cancer
|
June 26, 2015
A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52)
Gunter von Minckwitz, Bettina Conrad, Toralf Reimer, et al.
Breast Cancer Research : BCR
|
September 2, 2022
Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial
Cornelia Kolberg-Liedtke, Friedrich Feuerhake, Madlen Garke, et al.
International Journal of Cancer
|
June 5, 2019
Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial
Oleg Gluz, Cornelia Kolberg-Liedtke, Aleix Prat, et al.
Breast Cancer Research and Treatment
|
March 19, 2017
Efficacy and safety of nab-paclitaxel 125 mg/m<sup>2</sup> and nab-paclitaxel 150 mg/m<sup>2</sup> compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69)
Jenny Furlanetto, Christian Jackisch, Michael Untch, et al.
Journal for Immunotherapy of Cancer
|
May 8, 2021
Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial
Monika Graeser, Friedrich Feuerhake, Oleg Gluz, et al.
Molecular Cancer
|
March 27, 2025
Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trial
Darren Korbie, Clare Stirzaker, Oleg Gluz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 15, 2019
NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto
Michael Untch, Christian Jackisch, Andreas Schneeweiss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 7, 2022
De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial
Oleg Gluz, Ulrike Nitz, Cornelia Kolberg-Liedtke, et al.
Page
of 2